Literature DB >> 10924725

Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL.

C C Hsieh1, M H Yen, H W Liu, Y T Lau.   

Abstract

Oxidized low-density lipoprotein (oxLDL) plays a key role in the development of atherogenesis, partly by causing injury to vascular cells. However, different preparations of LDL, methods of oxidation, and/or active components often produce cellular effects of various degrees. To explore the quantitative relationship between dose and level of oxidation of the oxLDL utilized, we employed combinations of different levels of oxidation and concentrations of oxLDL to induce cell death in cultured vascular smooth muscle cells (VSMC). We also examined the effect of lysophosphatidylcholine (lysoPC), a putative active component of oxLDL, on VSMCs by determining, in parallel with a cytotoxicity test (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay), DNA fragmentation ([3H]thymidine release), and flow cytometric analyses. We found that oxLDL caused cytotoxicity in an oxidative level- and dose-dependent manner, lysoPC also caused dose-dependent cytotoxicity with or without serum. Fragmentation of DNA was observed in both oxLDL- and lysoPC-treated VSMCs. Furthermore, lysoPC-induced DNA ladder was also demonstrated by gel electrophoresis at a concentration of 25 micromol/l or higher. Flow cytometric analysis yielded similar results for oxLDL- and lysoPC-treated VSMC; namely, an accumulation in the fraction of cells in G(0)/G(1) phase with a reciprocal change in S-phase fraction. Membrane phosphatidylserine exposure, detected by annexin V staining, provided additional evidence that lysoPC induced significant apoptosis in VSMC. Taken together, the degree of oxLDL-induced cytotoxicity/apoptosis of VSMC depended on combined effects of oxLDL concentration and oxidative level. Moreover, lysoPC also elicited a dose-dependent apoptosis in addition to cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924725     DOI: 10.1016/s0021-9150(00)00453-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

1.  Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis.

Authors:  Weidong Zhang; Guang Sun; Dawn Aitken; Sergei Likhodii; Ming Liu; Glynn Martin; Andrew Furey; Edward Randell; Proton Rahman; Graeme Jones; Guangju Zhai
Journal:  Rheumatology (Oxford)       Date:  2016-05-09       Impact factor: 7.580

2.  The signal molecule lysophosphatidylcholine in Eschscholzia californica is rapidly metabolized by reacylation.

Authors:  Wieland Schwartze; Werner Roos
Journal:  Planta       Date:  2008-09-20       Impact factor: 4.116

Review 3.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

4.  Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system.

Authors:  Rieko Muramatsu; Mariko Kuroda; Ken Matoba; Hsiaoyun Lin; Chisato Takahashi; Yoshihisa Koyama; Toshihide Yamashita
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

5.  Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.

Authors:  Dallit Mannheim; Joerg Herrmann; Daniele Versari; Mario Gössl; Fredric B Meyer; Joseph P McConnell; Lilach O Lerman; Amir Lerman
Journal:  Stroke       Date:  2008-03-20       Impact factor: 7.914

6.  Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.

Authors:  Kasey C Vickers; Colin T Maguire; Robert Wolfert; Alan R Burns; Michael Reardon; Richard Geis; Paul Holvoet; Joel D Morrisett
Journal:  J Lipid Res       Date:  2009-04-09       Impact factor: 5.922

7.  Inhibitory effects of lysophosphatidylcholine on the dopaminergic system.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Kennie R Shepherd; Nazarius S Lamango; Karam F A Soliman; Clivel G Charlton
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

8.  Impact of lysophosphatidylcholine on survival and function of UEA-1(+)acLDL (+) endothelial progenitor cells in patients with coronary artery disease.

Authors:  Seong Hun Hong; Hyun Hee Jang; So Ra Lee; Kyung Hye Lee; Jong Shin Woo; Jin Bae Kim; Woo-Shik Kim; Byung Il Min; Ki Ho Cho; Kwon Sam Kim; Xianwu Cheng; Weon Kim
Journal:  Heart Vessels       Date:  2014-02-09       Impact factor: 2.037

9.  Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome.

Authors:  Joerg Herrmann; Dallit Mannheim; Christine Wohlert; Daniele Versari; Fredric B Meyer; Joseph P McConnell; Mario Gössl; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2009-08-17       Impact factor: 29.983

10.  Bioactive lysophospholipids generated by hepatic lipase degradation of lipoproteins lead to complement activation via the classical pathway.

Authors:  Wanchao Ma; David C Paik; Gaetano R Barile
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.